BCL2L11 and cancer: Indeed, this general lesson may be applied to cancers where we have found that the BIM deletion does play a part in clinical drug resistance [17], and supports the use of judiciously chosen combination therapies to overcome BIM deletion-mediated drug resistance in these patients.